Foghorn Therapeutics reported progress in its Phase 1 trial of FHD-909, a selective SMARCA2 inhibitor targeting NSCLC with SMARCA4 mutations, showing promising preclinical results in combination with anti-PD-1 antibodies. The company is also advancing selective CBP and EP300 degrader programs for breast cancer and multiple myeloma, with IND filings expected in 2027. Financially, Foghorn holds $184 million in cash and equivalents, supporting operations into the first half of 2028. These developments highlight Foghorn's expanding pipeline in difficult-to-treat cancers and ongoing collaboration with Lilly.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
Fundstrat's Granny Shot US-Small & Mid-Cap ETF (GRNJ) has delivered strong year-to-date returns, beating similar ETFs like VOT and VOO despite its higher 0.75% expense ratio. The fund targets stocks at the intersection of major secular trends, partic...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
